



CV QUEST 2009:

Leaders and Legacies in Clinical Trials

Wednesday, October 28, 2009

ACCREDITED SYMPOSIUM

Wednesday, October 28, 2009

6:30 - 7:00 a.m. - Breakfast
7:00 - 9:00 a.m. - Satellite Symposium

LOCATION:

The Fairmont Hotel Macdonald,
10065-100 Street, Edmonton, Alberta, Canada

MEETING ROOM:

Empire Ballroom and Foyer

Learn about indispensable findings from the world's leading researchers and clinical trial groups by visiting www.ccrnmd.com

Co-Chairs:



Milan Gupta, MD, FRCPC
Associate Clinical Professor of Medicine,
McMaster University
Assistant Professor of Medicine,
University of Toronto
Division of Cardiology,
William Osler Health Centre,
Brampton, Ontario



Subodh Verma, MD, PhD, FRCSC, FAHA
Cardiac Surgeon
St-Michael's Hospital
Associate Professor
University of Toronto
Canada Research Chair in Atherosclerosis
Director, Traineeship in Atherosclerosis
Toronto, Ontario

Faculty:



Deepak L. Bhatt, MD, FACC, FAHA
Chief of Cardiology
VA Boston Healthcare System
Director, Integrated Interventional
Cardiovascular Program
Brigham and Women's Hospital and the
VA Boston Healthcare System
Senior Investigator, TIMI Group
Boston, Massachusetts, USA



Jean-Claude Tardif, MD
Director, MHI Research Centre
Professor of Medicine
Université de Montréal Research
Chair in Atherosclerosis
Montreal Heart Institute
Université de Montréal
Montreal, Quebec



Robert M. Califf, MD
Vice Chancellor for Clinical Research
Duke University Medical Center
Director, Duke Translational Medicine
Institute, Durham, North Carolina



Eva Lonn, MD, MSc, FRCPC, FACC
Professor of Medicine,
McMaster University
Hamilton Health Sciences General Site
Hamilton, Ontario

AGENDA:

Opening Remarks

The TIMI Experience

The Population Health Research Institute Experience in Clinical Trials and Epidemiology

The Montreal Heart Institute Coordinating Centre (MHICC) and the Canadian Atherosclerosis Imaging Network (CAIN)

The Duke Clinical Research Institute

Discussion

Closing Remarks

7:00 - 9:00 a.m.

Dr. Milan Gupta

Dr. Deepak Bhatt

Dr. Eva Lonn

Dr. Jean-Claude Tardif

Dr. Robert Califf

All

Dr. Subodh Verma

WHO SHOULD ATTEND: CV surgeons, cardiologists, internal medicine specialists, endocrinologists, fellows, residents and nurses interested in these disciplines.

LEARNING OBJECTIVES:

Throughout and following this session, the learner will:

1. Review key findings from the Thrombolysis in Myocardial Infarction (TIMI) Experience
2. Be familiar with developments in The Montreal Heart Institute Coordinating Centre (MHICC) and the Canadian Atherosclerosis Imaging Network (CAIN)
3. Consider the evolution and lessons learned from the Duke Clinical Research Institute
4. Examine The Population Health Research Institute Experience in Clinical Trials and Epidemiology



The Canadian Cardiovascular Research Network (CCRN) is a not-for-profit academic research organization that aims to foster basic, translational, clinical and population level research efforts, and generate new knowledge to improve cardiovascular care in Canada. An additional mandate is to develop state-of-the-art knowledge integration platforms that feature multidisciplinary and inter-specialty collaboration focusing on the future of health care delivery, research and academia-industry interface. At the present time, CCRN is actively involved in basic studies evaluating the role of adipokines in atherosclerosis, translational studies in cardiometabolic risk, clinical trials in atherothrombosis, and population based studies in minority groups.

This program will be comprised of internationally recognized principal investigators of major cardiovascular clinical trials. These four distinguished leaders will describe their clinical stream and explain how their investigations and related work have contributed to the current understanding around morbidity and mortality data as well as how their work has contributed significantly to the standard of care in the cardiovascular environment in which we practice today.

The work of these researchers touches on a variety of areas encompassing the investigation of particular therapies including acute coronary reperfusion; the use of aspirin; beta blockers; and ACE inhibitors; and the reduction of blood cholesterol, the intricacies of the RAAS, and the basics on designing and implementing a large, simple trial. Their work has challenged our past and current understanding on the efficacy of therapies such as calcium channel blockers; maintenance heparin use; nitroglycerin; and magnesium, as well as challenges us to examine the studies we design and evaluate. These investigators are well researched in strategies related to their specific area of expertise and plan to bring us 'key learnings' from various realms.

Clearly, the work of these investigators has provided us with key solutions for patient management and their data has been instrumental in influencing the treatment guidelines in Canada and in our own practices. Their knowledge and thoughtful investigation has demonstrated the expertise we should come to expect as we collectively dig deeper towards further understanding in the cardiovascular area and as we plan and execute future research. This program will benefit CV surgeons, cardiologists, internal medicine specialists, endocrinologists, fellows, residents, nurses and pharmacists interested in these disciplines.

THIS EVENT HAS BEEN MADE POSSIBLE THROUGH GRANT SUPPORT TO THE CANADIAN CARDIOVASCULAR RESEARCH NETWORK FROM THE FOLLOWING SPONSORS:

Eli Lilly Canada Inc., Merck Frosst Canada Ltd. / Schering-Plough Canada Inc. (joint venture), Sorin Group Canada, Boehringer Ingelheim (Canada) Ltd., Novartis Pharmaceuticals Canada Inc., Pfizer Canada, Sanofi-aventis / Bristol Myers Squibb (joint venture), Li-Ka Shing King Saud University St. Michael's Hospital Collaborative Program, Solvay Pharma

This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program.

This program has been reviewed and co-developed by the



for a maximum of 2 hours of Section 1 credits.